Matches in Nanopublications for { ?s ?p ?o <http://bio2rdf.org/drugbank:DB06414_nanopub.RAKh4jp_pwJ0cmSj1pot9a5ZLoIpdDZDRO9VRwmq23hAc#assertion>. }
Showing items 1 to 19 of
19
with 100 items per page.
- drugbank:DB06414 type drugbank_vocabulary:Drug assertion.
- drugbank:DB06414 label "Etravirine [drugbank:DB06414]" assertion.
- drugbank:DB06414 seeAlso DB06414 assertion.
- drugbank:DB06414 seeAlso etravirine.html assertion.
- drugbank:DB06414 seeAlso intelence-drug.htm assertion.
- drugbank:DB06414 identifier "drugbank:DB06414" assertion.
- drugbank:DB06414 description "Etravirine is an antiretroviral agent more specifically classified as a Non-Nucleoside Reverse Transcriptase Inhibitor(NNRTI). Etraverine is used clinically for the treatment of human immunodeficiency virus type 1 (HIV-1) infection. On January 18, 2007, the FDA granted accelerated approved for the use of etravirine 100mg tablets in the treatment of adult HIV-1 infection documented to be resistant to therapy with other NNRTIs and antiretroviral agents. On March 26, 2012, approval was extended for use in treatment-experienced pediatric patients 6 to 18 years of age, weighing at least 16 kg. Etravarine must always be used in combination with other antiretroviral drugs. Etravirine exerts its effects via direct inhibition of the reverse transcriptase enzyme of human immunodeficiency virus type 1 (HIV-1), and consequently blocks DNA-dependent and RNA-dependent polymerase activity. Etravirine does not inhibit human DNA polymerase alpha, beta or gamma. Common side effects of use include mild to moderate rash within the first 6 weeks of therapy, nausea, diarrhea and peripheral neuropathy. Patients are advised to immediately contact their healthcare provider if a rash develops. In 2009, postmarketing case reports of Stevens-Johnson Syndrome, toxic epidermal necrolysis, erythema multiforme, and other hypersensitivity reactions lead to a revision of etravirine's "Warnings and Precautions," as well as notification of health care providers. In 2013, reports of Autoimmune disorders (such as Graves’ disease, polymyositis, and Guillain-Barré syndrome) in the setting of immune reconstitution, as well as more in depth information about the development of rashes in patients taking etravirine, lead to a modification of etravirine's monograph." assertion.
- drugbank:DB06414 title "Etravirine" assertion.
- drugbank:DB06414 bio2rdf_vocabulary:identifier "DB06414" assertion.
- drugbank:DB06414 bio2rdf_vocabulary:namespace "drugbank" assertion.
- drugbank:DB06414 bio2rdf_vocabulary:uri "http://bio2rdf.org/drugbank:DB06414" assertion.
- drugbank:DB06414 bio2rdf_vocabulary:x-identifiers.org DB06414 assertion.
- drugbank:DB06414 drugbank_vocabulary:drugbank-id "DB06414" assertion.
- drugbank:DB06414 drugbank_vocabulary:x-cas cas:269055-15-4 assertion.
- drugbank:DB06414 drugbank_vocabulary:x-atc atc:J05AG04 assertion.
- drugbank:DB06414 drugbank_vocabulary:x-chebi chebi:63589 assertion.
- drugbank:DB06414 drugbank_vocabulary:x-kegg kegg:D04112 assertion.
- drugbank:DB06414 drugbank_vocabulary:x-wikipedia wikipedia:Etravirine assertion.
- drugbank:DB06414 drugbank_vocabulary:x-ndc ndc:53808-0787-1 assertion.